Pfizer's BRAFTOVI® Combination Regimen Cuts the Risk of Death in Half for Patients with BRAF V600E-Mutant Metastatic Colorectal CancerBusiness Wire • 05/30/25
Collaborations for Change: AUA and Pfizer Select Recipients for $1.5 Million Grant Program to Improve Advanced Prostate Cancer CareGlobeNewsWire • 05/29/25
Hearing Against Pfizer Set For 30 May In Contraceptive ‘Depo-Provera' Multidistrict Litigation Overseen By Levin PapantonioBusiness Wire • 05/28/25
Investing In The Promising PD1/VEGF Bispecific - Pfizer And Instil Could Be Good CandidatesSeeking Alpha • 05/26/25
U.S. Pharmaceutical Imports Might Soon Face Tariffs: 3 Stocks That Could Tumble as a ResultThe Motley Fool • 05/24/25
Astellas and Pfizer's XTANDI™ (enzalutamide) Shows Long-Term Overall Survival in Metastatic Hormone-Sensitive Prostate CancerPRNewsWire • 05/22/25
MRNA, PFE Stocks Jump Despite FDA's Stricter Standards for COVID-19 ShotsZacks Investment Research • 05/21/25
Buy 3 Wide Moat Stocks With Double-Digit Near-Term Upside PotentialZacks Investment Research • 05/20/25